Current guidelines18 recommend treating patients with heart failure with quadruple therapy, including angiotensin receptor-neprilysin inhibitors, SGLT2 inhibitors, β blockers, and mineralocorticoid receptor antagonists. The gene discussed is NR3C2; the disease is heart failure.